Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 3/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875917 | 0.91 | GLRA1 (0.50) | RXRARXRBRXRGMRGPRX4ELANE | |
| SCHEMBL3712428 | 0.84 | CA12 (0.42) | KMT2A | |
| SCHEMBL3963472 | 0.79 | RAB9A (0.49) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL793724 | 0.78 | MEN1 (0.65) | MEN1KMT2ARXRARXRBRXRG | |
| SCHEMBL11762649 | 0.77 | RXRA (0.61) | MEN1KMT2ARXRARXRBRXRG | |
| Hydrochloric Acid SCHEMBL514496 | 0.77 | MEN1 (0.63) | MEN1KMT2ARXRARXRBRXRG | |
| SCHEMBL14660694 | 0.77 | MEN1 (0.63) | MEN1KMT2ARXRARXRBRXRG | |
| SCHEMBL7168025 | 0.75 | RXRA (0.62) | MEN1KMT2ARXRAMRGPRX4SMN1; SMN2 | |
| SCHEMBL15673277 | 0.75 | RXRA (0.62) | MEN1KMT2ARXRAMRGPRX4SMN1; SMN2 | |
| SCHEMBL30102546 | 0.75 | RXRA (0.62) | MEN1KMT2ARXRAMRGPRX4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080070850-A1 | GALLOTANNINS AND ELLIGITANNINS AS REGULATORS OF CYTOKINE RELEASE | THE PENN STATE RESEARCH FOUNDATION (US) | 2008-03-20 | — | — | US | disclosed |
| US-7288273-B1 | Gallotannins and ellagitannins as regulators of cytokine release | THE PENN STATE RESEARCH FOUNDATION (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1232169-A1 | GALLOTANNINS AND ELLAGITANNINS AS REGULATORS OF CYTOKINE RELEASE | THE PENN STATE RESEARCH FOUNDATION (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001036436-A1 | GALLOTANNINS AND ELLAGITANNINS AS REGULATORS OF CYTOKINE RELEASE | THE PENN STATE RESEARCH FOUNDATION (US) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070850-A1 | GALLOTANNINS AND ELLIGITANNINS AS REGULATORS OF CYTOKINE RELEASE | IL2, IL6, TNF | MEN1 2640/4885KMT2A 3946/4885RXRA 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.